Advertisement


Mazyar Shadman, MD, MPH, on Large B-Cell Lymphoma: Autologous Transplantation vs CAR T-Cell Therapy

2023 ASH

Advertisement

Mazyar Shadman, MD, MPH, of the University of Washington, discusses new data suggesting that in patients with relapsed large B-cell lymphoma who achieve a complete response, treatment with autologous transplantation may be associated with a lower relapse rate and improved progression-free survival compared with CAR T-cell therapy, including those with early treatment failure (Abstract 781).



Related Videos

Multiple Myeloma

Pieter Sonneveld, MD, PhD, on Newly Diagnosed Multiple Myeloma: Phase III Findings on Daratumumab Plus Bortezomib, Lenalidomide, and Dexamethasone

Pieter Sonneveld, MD, PhD, of the Netherland’s Erasmus MC Cancer Institute, discusses primary results from the Perseus trial, showing that for patients with newly diagnosed multiple myeloma who are eligible for transplantation, the combination of daratumumab plus bortezomib, lenalidomide, and dexamethasone, followed by daratumumab and lenalidomide maintenance, may be a new standard of care (Abstract LBA1).

Multiple Myeloma

Darren Denjay Pan, MD, on Multiple Myeloma: Inflammatory Biomarkers and Outcomes After CAR T-Cell Therapy

Darren Denjay Pan, MD, of Tisch Cancer Institute and the Icahn School of Medicine at Mount Sinai, discusses his findings on risk assessment of CAR T-cell therapy for patients with multiple myeloma. Higher fibrinogen and ferritin values at baseline were associated with inferior overall survival after CAR T-cell therapy, even after controlling for tumor burden. Higher baseline absolute lymphocyte count was also associated with higher risk and grade of immune effector cell–associated neurotoxicity syndrome, an important toxicity to consider for patients receiving CAR T (Abstract 92).

Hematologic Malignancies

Andrew Srisuwananukorn, MD, on Myelofibrosis vs Essential Thrombocythemia: A Potential New Clinical Decision Tool

Andrew Srisuwananukorn, MD, of The Ohio State University Comprehensive Cancer Center, discusses a novel artificial intelligence model that can distinguish between prefibrotic primary myelofibrosis and essential thrombocythemia. This proposed model may assist clinicians in identifying patients who may benefit from disease-specific therapies or enrollment in clinical trials (Abstract 901).

Hematologic Malignancies
Genomics/Genetics

Potential Clinical Uses of Identifying New Hematologic Malignancy Predisposition Gene

Hamish S. Scott, PhD, and Chris Hahn, PhD, both of Australia’s SA Pathology and Centre for Cancer, discuss ERG, a new predisposition gene for bone marrow failure and hematologic malignancy. Identifying causal germline ERG variants has direct clinical implications for diagnosis, counseling, surveillance, and treatment strategies, according to Drs. Scott and Hahn (Abstract LBA5).

Lymphoma

Bijal D. Shah, MD, on Previously Treated Mantle Cell Lymphoma: New Findings on Brexucabtagene Autoleucel and Pirtobrutinib

Bijal D. Shah, MD, of Moffitt Cancer Center and Research Institute, discusses a matching-adjusted indirect comparison of brexucabtagene autoleucel and pirtobrutinib in patients with relapsed or refractory mantle cell lymphoma who have been previously treated with a BTK inhibitor (Abstract 5136).

Advertisement

Advertisement




Advertisement